Total Payments
$12,169
2024 Payments
$5,516
Companies
59
Transactions
380
Medicare Patients
1,474
Medicare Billing
$189,230
Payment Breakdown by Category
Food & Beverage$7,173 (59.0%)
Consulting$4,570 (37.6%)
Travel$381.96 (3.1%)
Other$43.20 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,173 | 374 | 59.0% |
| Consulting Fee | $4,570 | 1 | 37.6% |
| Travel and Lodging | $381.96 | 3 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43.20 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $5,227 | 14 | $0 (2024) |
| Biogen, Inc. | $615.87 | 21 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $552.09 | 56 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $482.52 | 40 | $0 (2021) |
| ABBVIE INC. | $469.32 | 19 | $0 (2024) |
| GENZYME CORPORATION | $419.75 | 17 | $0 (2020) |
| Genentech USA, Inc. | $345.61 | 15 | $0 (2024) |
| UCB, Inc. | $318.85 | 12 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $281.17 | 18 | $0 (2020) |
| EMD Serono, Inc. | $258.64 | 11 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,516 | 24 | Eisai Inc. ($5,176) |
| 2023 | $382.62 | 12 | ABBVIE INC. ($198.78) |
| 2022 | $150.26 | 5 | ABBVIE INC. ($102.06) |
| 2021 | $595.46 | 34 | Biohaven Pharmaceuticals, Inc. ($143.94) |
| 2020 | $824.32 | 38 | Alexion Pharmaceuticals, Inc. ($133.71) |
| 2019 | $1,261 | 82 | Supernus Pharmaceuticals, Inc. ($317.70) |
| 2018 | $1,754 | 102 | Biogen, Inc. ($248.76) |
| 2017 | $1,684 | 83 | Teva Pharmaceuticals USA, Inc. ($301.84) |
All Payment Transactions
380 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Rare Disease | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Neurology | ||||||
| 11/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Food and Beverage | In-kind items and services | $31.59 | General |
| Category: Neurology | ||||||
| 09/30/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $32.05 | General |
| Category: Neurology | ||||||
| 09/09/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: EPILEPSY | ||||||
| 08/12/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Neuroscience | ||||||
| 08/02/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $123.28 | General |
| Category: Neurology | ||||||
| 07/31/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $49.96 | General |
| Category: PSYCHIATRY | ||||||
| 07/19/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $4,570.00 | General |
| Category: Neurology | ||||||
| 07/16/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $49.95 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $47.28 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $36.37 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $17.97 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $16.31 | General |
| Category: Neurology | ||||||
| 06/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $12.37 | General |
| Category: Neurology | ||||||
| 06/21/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $222.31 | General |
| Category: Neurology | ||||||
| 06/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $63.41 | General |
| Category: Neurology | ||||||
| 06/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Neurology | ||||||
| 06/20/2024 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Immunology and Neurology | ||||||
| 05/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: Neurology | ||||||
| 04/09/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Musculoskeletal | ||||||
| 03/26/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Immunology | ||||||
| 01/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $31.63 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2023 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 361 | 432 | $130,766 | $42,764 |
| 2022 | 4 | 86 | 87 | $29,384 | $9,919 |
| 2021 | 9 | 508 | 600 | $177,498 | $69,945 |
| 2020 | 9 | 519 | 597 | $187,870 | $66,601 |
Total Patients
1,474
Total Services
1,716
Medicare Billing
$189,230
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 131 | 165 | $45,045 | $15,944 | 35.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 101 | 102 | $33,456 | $10,803 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 76 | 96 | $18,336 | $6,228 | 34.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 22 | 35 | $19,250 | $6,125 | 31.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $10,311 | $2,986 | 29.0% |
| 62270 | Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test | Facility | 2023 | 11 | 13 | $4,368 | $676.65 | 15.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 42 | 43 | $14,104 | $4,802 | 34.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 20 | 20 | $6,700 | $2,255 | 33.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $5,200 | $1,802 | 34.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 13 | $3,380 | $1,060 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 151 | 209 | $54,340 | $20,728 | 38.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 61 | $18,300 | $8,771 | 47.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 57 | 76 | $20,748 | $6,538 | 31.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 38 | 38 | $12,730 | $5,192 | 40.8% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 50 minutes | Office | 2021 | 20 | 23 | $9,660 | $5,039 | 52.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $11,178 | $4,695 | 42.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $13,257 | $4,554 | 34.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 53 | $7,791 | $3,451 | 44.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $8,694 | $3,308 | 38.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 27 | 27 | $8,735 | $3,096 | 35.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 19 | $5,700 | $2,369 | 41.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 19 | 19 | $6,365 | $2,204 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 154 | 205 | $53,036 | $16,841 | 31.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 87 | 99 | $29,700 | $11,259 | 37.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 78 | 78 | $26,130 | $10,359 | 39.6% |
About Dr. Dan Gzesh, MD
Dr. Dan Gzesh, MD is a Vascular Neurology healthcare provider based in Abington, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417984923.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dan Gzesh, MD has received a total of $12,169 in payments from pharmaceutical and medical device companies, with $5,516 received in 2024. These payments were reported across 380 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($7,173).
As a Medicare-enrolled provider, Gzesh has provided services to 1,474 Medicare beneficiaries, totaling 1,716 services with total Medicare billing of $189,230. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Vascular Neurology
- Other Specialties Neurology
- Location Abington, PA
- Active Since 06/28/2006
- Last Updated 01/22/2021
- Taxonomy Code 2084V0102X
- Entity Type Individual
- NPI Number 1417984923
Products in Payments
- Leqembi (Drug) $5,176
- TROKENDI XR (Drug) $520.63
- TYSABRI (Biological) $422.54
- COPAXONE (Drug) $376.71
- Briviact (Drug) $290.47
- QULIPTA (Drug) $281.97
- APTIOM (Drug) $281.17
- UBRELVY (Drug) $216.07
- Hizentra (Biological) $207.25
- ADUHELM (Biological) $193.33
- TEGSEDI (Drug) $188.45
- AUBAGIO (Drug) $185.65
- LEMTRADA (Drug) $181.70
- OCREVUS (Biological) $180.39
- Soliris (Drug) $149.19
- BOTOX (Biological) $145.28
- NURTEC ODT (Drug) $143.94
- VYVGART HYTRULO (Drug) $142.51
- RHOGAM (Drug) $123.69
- AMPLATZER Vascular Plugs (Device) $99.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.